Cascade Signals of Papaverine Inhibiting LPS-Induced Retinal Microglial Activation

Ting Zhou1, Yu Zhu2

  • 1Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, East Jianshe Road, Zhengzhou, 450001, People's Republic of China.

Insights

Papaverine inhibits lipopolysaccharide (LPS)-induced microglial activation by modulating the cAMP/PKA and MEK/Erk pathways. This action reduces inflammatory factors and promotes anti-inflammatory factors, offering neuroprotection.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Microglial activation by lipopolysaccharide (LPS) contributes to neuroinflammation.
  • Papaverine has demonstrated potential in inhibiting LPS-induced microglial activation.

Purpose of the Study:

  • To investigate the role of the MEK/Erk pathway in papaverine's inhibition of primary retinal microglial activation.
  • To explore the relationship between the cAMP/PKA and MEK/Erk pathways in this process.

Main Methods:

  • Established an LPS-induced primary retinal microglia activation model in SD rats.
  • Utilized Western blotting, RT-PCR, and ELISA to detect protein phosphorylation and gene expression.
  • Administered cAMP inhibitor Rp-isomer, PKA inhibitor H89, and MEK inhibitor U0126.

Main Results:

  • LPS upregulated MEK phosphorylation, which was inhibited by papaverine.
  • U0126 significantly reduced TNF-α and IL-1β while increasing IL-10 expression.
  • Rp-isomer and H89 increased MEK and Erk phosphorylation levels.

Conclusions:

  • Papaverine inhibits inflammatory factors and promotes anti-inflammatory factors via cAMP/PKA and MEK/Erk pathways, reducing LPS-induced microglial activation.
  • The MEK/Erk pathway is partially regulated by cAMP/PKA, providing a basis for papaverine's neuroprotective effects.

Related Concept Videos

Intracellular Signaling Cascades01:24

Intracellular Signaling Cascades

Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...
53.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.2K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K